Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

DNA Ginkgo Bioworks Holdings, Inc.

Abstract: The control problem of dynamic systems that undergo sudden changes and rely on past data is known to be challenging to solve and has received a lot of attention in the past years. Meanwhile, ...